Company intelligence / Profile preview

MITICURE

Sendai, Miyagi, Japan

Ownership: Private
Development stage: Other

Overview

Miticure is a Japanese biotechnology company dedicated to developing innovative therapies for mitochondrial diseases. The company's lead program, MC-001, is a small molecule designed to restore mitochondrial function in patients with severe metabolic disorders such as Leigh syndrome. Founded as a spin-off from Tohoku University, Miticure leverages deep expertise in mitochondrial biology to address significant unmet medical needs in rare genetic conditions. The company aims to expand its pipeline to include other mitochondrial-related pathologies, utilizing its proprietary screening and development capabilities.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Tohoku University

Beyond the preview

Go deeper on MITICURE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MITICURE.

Explore the full profile